Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
Back to Results

  • Comparison of Haploidentical Donor Transplant versus 7/8 HLA-mismatched Unrelated Donor Allogeneic Stem Cell Transplant in Acute Myeloid Leukemia and Myelodysplastic Syndrome

    Cancer Categories
    • Hematologic (Blood Cancers)
    Karmanos Trial ID
    • 2020-131
    Age Group
    • Adult
    Scope
    • Local
    PhaseClick for Clinical Trial Phase DefinitionQuestions, please contact us
    • N/A
    Principal Investigator
    • Image of Dipenkumar Modi , M.D.
      Dipenkumar
      Modi, M.D.
      Oncology - Hematology, Oncology - Medical View Profile

    Objective:

    The objectives are to estimate acute GVHD (aGVHD) rate, chronic GVHD (cGVHD) rate, relapse-free survival (RFS), overall survival (OS), GVHD-free relapse-free survival (GRFS), relapse rate, and non-relapse mortality (NRM) for AML and MDS patients by HIDT and 7/8 HLA-MMUD separately.
    Request an Appointment
    Refer a Patient
    NCI Dictionary of Cancer Terms
    KCI Clinical Trials App
    • Locations

    Locations

    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266